These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25707537)

  • 21. Killing time for cancer cells.
    Klein S; McCormick F; Levitzki A
    Nat Rev Cancer; 2005 Jul; 5(7):573-80. PubMed ID: 15965492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RETRACTED: Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
    Morgillo F; D'Aiuto E; Troiani T; Martinelli E; Cascone T; De Palma R; Orditura M; De Vita F; Ciardiello F
    Lung Cancer; 2011 Mar; 71(3):283-90. PubMed ID: 20619923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition.
    Goldman A; Majumder B; Dhawan A; Ravi S; Goldman D; Kohandel M; Majumder PK; Sengupta S
    Nat Commun; 2015 Feb; 6():6139. PubMed ID: 25669750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells.
    Tan TT; White E
    Adv Exp Med Biol; 2008; 615():81-104. PubMed ID: 18437892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consequences of feedback in signal transduction for targeted therapies.
    Klinger B; Blüthgen N
    Biochem Soc Trans; 2014 Aug; 42(4):770-5. PubMed ID: 25109956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptotic pathways in tumor progression and therapy.
    Melet A; Song K; Bucur O; Jagani Z; Grassian AR; Khosravi-Far R
    Adv Exp Med Biol; 2008; 615():47-79. PubMed ID: 18437891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential role of the antiproliferative cytokine beta-galactoside binding protein in cancer therapy.
    Mallucci L; Wells V
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1228-33. PubMed ID: 16370387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptosis: a link between cancer genetics and chemotherapy.
    Johnstone RW; Ruefli AA; Lowe SW
    Cell; 2002 Jan; 108(2):153-64. PubMed ID: 11832206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Power-Law Modeling of Cancer Cell Fates Driven by Signaling Data to Reveal Drug Effects.
    Zhang F; Wu M; Kwoh CK; Zheng J
    PLoS One; 2016; 11(10):e0165049. PubMed ID: 27764199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pan-cancer network disorders revealed by overall and local signaling entropy.
    Feng L; Sun YD; Li C; Li YX; Chen LN; Zeng R
    J Mol Cell Biol; 2021 Dec; 13(9):622-635. PubMed ID: 34097054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is TRAIL the holy grail of cancer therapy?
    Newsom-Davis T; Prieske S; Walczak H
    Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
    Vyse S; McCarthy F; Broncel M; Paul A; Wong JP; Bhamra A; Huang PH
    J Proteomics; 2018 Jan; 170():130-140. PubMed ID: 28842319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The p53 protein and its molecular network: modelling a missing link between DNA damage and cell fate.
    Eliaš J; Dimitrio L; Clairambault J; Natalini R
    Biochim Biophys Acta; 2014 Jan; 1844(1 Pt B):232-47. PubMed ID: 24113167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adhesion dependent signalling in the tumour microenvironment: the future of drug targetting.
    Bewick MA; Lafrenie RM
    Curr Pharm Des; 2006; 12(22):2833-48. PubMed ID: 16918414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.